Therapeutic subgroup
A10 – ANTIDIABETIKA
- Anatomical main group A: ALIMENTÄRES SYSTEM UND STOFFWECHSEL
45Decisions
133Patient groups
Added benefit by patient group
- Considerable6
- Minor18
- Non-quantifiable1
- Not proven108
Subgroups
- A10A INSULINE UND ANALOGA 9 decisions
- A10B BLUTZUCKERSENKENDE MITTEL, EXKL. INSULINE 35 decisions
- A10X ANDERE ANTIDIABETIKA 1 decision
Decisions, newest first
- 2026-08-20MounjaroTirzepatidNot proven
- 2026-08-06TeizeildTeplizumabNon-quantifiable
- 2025-02-20AwiqliInsulin icodecNot proven
- 2025-02-20AwiqliInsulin icodecNot proven: 4 of 4 patient groups
- 2024-06-20JardianceEmpagliflozinNot proven
- 2024-05-02MounjaroTirzepatidMinor: 1 of 8 patient groupsNot proven: 7 of 8 patient groups
- 2024-02-01JardianceEmpagliflozinNot proven
- 2023-09-21TrulicityDulaglutidNot proven
- 2023-08-17ForxigaDapagliflozinMinor
- 2022-09-15JardianceEmpagliflozinMinor
- 2022-06-16ForxigaDapagliflozinNot proven: 2 of 2 patient groups
- 2022-05-19SteglatroErtugliflozinNot proven: 8 of 8 patient groups
- 2022-02-17ForxigaDapagliflozinConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2022-01-06JardianceEmpagliflozinMinor
- 2021-05-20ForxigaDapagliflozinConsiderable
- 2020-10-15SuliquaInsulin glargin/LixisenatidNot proven: 2 of 2 patient groups
- 2020-07-16TrulicityDulaglutidMinor: 2 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2019-12-19ForxigaDapagliflozinMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
- 2019-12-19XigduoDapagliflozin/MetforminMinor: 3 of 6 patient groupsNot proven: 3 of 6 patient groups
- 2019-11-22GlyxambiEmpagliflozin/LinagliptinNot proven
- 2019-05-16TresibaInsulin degludecNot proven: 2 of 2 patient groups
- 2019-05-02OzempicSemaglutidMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
- 2019-03-22JanuviaSitagliptinMinor
- 2018-11-01SteglujanErtugliflozin/SitagliptinNot proven
- 2018-08-16SuliquaInsulin glargin/LixisenatidNot proven: 2 of 2 patient groups
- 2018-02-01KomboglyzeSaxagliptin/MetforminNot proven
- 2016-12-15JanumetSitagliptin/MetforminNot proven: 3 of 3 patient groups
- 2016-12-15JanuviaSitagliptinNot proven: 4 of 4 patient groups
- 2016-12-15KomboglyzeSaxagliptin/MetforminNot proven: 2 of 2 patient groups
- 2016-12-15OnglyzaSaxagliptinNot proven: 4 of 4 patient groups
- 2016-09-01SynjardyEmpagliflozin/MetforminNot proven: 6 of 6 patient groups
- 2016-09-01JardianceEmpagliflozinConsiderable: 4 of 10 patient groupsMinor: 1 of 10 patient groupsNot proven: 5 of 10 patient groups
- 2016-02-04XultophyInsulin degludec/LiraglutidNot proven
- 2015-10-15XultophyInsulin degludec/LiraglutidNot proven: 3 of 3 patient groups
- 2015-08-20TresibaInsulin degludecNot proven: 3 of 3 patient groups
- 2015-05-21GalvusVildagliptinNot proven
- 2015-02-05VokanametCanagliflozin/MetforminNot proven: 3 of 3 patient groups
- 2014-10-16TresibaInsulin degludecNot proven
- 2014-09-04InvokanaCanagliflozinNot proven: 5 of 5 patient groups
- 2013-10-01KomboglyzeSaxagliptin/MetforminNot proven
- 2013-10-01GalvusVildagliptinNot proven: 4 of 4 patient groups
- 2013-10-01EucreasVildagliptin/MetforminNot proven: 3 of 3 patient groups
- 2013-09-05Lyxumia LixisenatidNot proven: 4 of 4 patient groups
- 2013-05-16TrajentaLinagliptinNot proven
- 2013-02-21TrajentaLinagliptinNot proven: 3 of 3 patient groups
Data status: 2026-10-29